Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:25:10 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



Z:TEVA - TEVA PHARMACEUTICAL INDUSTRIES SPON ADS EACH REP 1 ORD SHS - http://www.tevapharm.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TEVA - Z1.013.71·13.924.013.81+0.554.110,278.3129,39123,11013.31  13.98  13.3114.465  7.08517:41:49Apr 1615 min RT 2¢

Recent Trades - Last 10 of 23110
Time ETExPriceChangeVolume
17:41:49Z13.710.463
17:35:39Z13.710.461
17:06:48Z13.920.675
16:16:01Z13.810.5661,161
16:10:21Z13.760.5122
16:08:32Z13.790.54103
16:06:19Z13.810.5610,005
16:03:17Z13.700.451
16:00:59Z13.810.564,922
16:00:57Z13.810.5676

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-16 17:43U:TEVANews ReleaseAlvotech and Teva Announce U.S. FDA Approval of SELARSDI(TM) (ustekinumab-aekn), biosimilar to Stelara(TM) (ustekinumab)
2024-04-16 08:00U:TEVANews ReleaseTeva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO(TM) (deutetrabenazine) Tablets
2024-04-11 08:30U:TEVANews ReleaseTeva Confirms Efficacy and Safety of AJOVY(TM) (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
2024-04-09 16:30U:TEVANews ReleaseTeva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
2024-04-06 13:00U:TEVANews ReleaseNew Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY(TM) (risperidone) Extended-Release Injectable Suspension at SIRS 2024
2024-04-04 08:30U:TEVANews ReleaseTeva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
2024-04-01 08:30U:TEVANews ReleaseClinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-'248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
2024-02-26 07:00U:TEVANews ReleaseTeva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO(TM) in China
2024-02-23 20:15U:TEVANews ReleaseAlvotech and Teva Announce U.S. Approval of SIMLANDI(TM) (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira(TM)
2024-02-20 08:30U:TEVANews ReleaseTeva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV- ¢ € ˜574) Antibody at the 2024 ECCO Annual Meeting
2024-01-31 07:00U:TEVANews ReleaseTeva Reports Growth in Fourth Quarter and Full Year 2023
2024-01-31 06:00U:TEVANews ReleaseTeva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
2024-01-02 16:30U:TEVANews ReleaseTeva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
2023-12-28 16:30U:TEVANews ReleaseTeva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-14 08:30U:TEVANews ReleaseTeva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
2023-12-06 02:00U:TEVANews ReleaseNew Post Hoc Phase 3 Data Analysis Shows AJOVY ‚ ® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
2023-11-30 08:30U:TEVANews ReleaseTeva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
2023-11-20 16:30U:TEVANews ReleaseTeva to Present at the 6th Annual Evercore ISI HealthCONx Conference